University of Twente
Jeannette Hofmeier
The goal of this comparative effectiveness trial is to study electrographic status epilepticus (ESE) treatment in comatose patients after cardiac arrest. The main questions the trial aims to answer are: * Does ESE treatment improve outcome? * What is the impact of ESE treatment on healthcare costs? Participants in the the intervention group will receive standard care completed with anti-seizure treatment. The control group will receive standard care without anti-seizure treatment.
Coma
Electrographic Status Epilepticus
anti-seizure medication + sedative agent(s)
NA
Rationale: Around 7500 comatose patients after cardiac arrest and resuscitation are admitted to intensive care units (ICUs) in the Netherlands and Belgium, yearly. Approximately half eventually dies from severe brain injury. EEG is used as a predictor of outcome, helping decide whether life sustaining therapies should be pursued or withdrawn. EEG shows epileptiform patterns meeting criteria for electrographic status epilepticus (ESE) in up to 10% of patients, with 80-100% case fatality. With the TELSTAR-1 trial, we showed that anti-seizure treatment of unselected patients with epileptiform patterns is not associated with a better outcome. However, it remains unclear whether treatment of (possible) ESE will improve outcome, or if ESE simply represents irreversible severe brain damage, in which case such treatment will be futile. This translates into ongoing practice variation. To provide comatose cardiac arrest survivors with the best medical treatment options, while at the same time preventing unnecessary costly ICU treatment, unequivocal evidence of efficacy or futility of ESE treatment is needed. Objectives: It is the primary objective to study whether ESE treatment improves outcome of comatose patients after cardiac arrest. It is the secondary objective to study the impact on healthcare costs of ESE treatment. Main trial endpoints: The primary outcome measure will be functional recovery expressed as the score on the extended Glasgow Outcome Scale (eGOS) at six months after cardiac arrest. The primary effect parameter will be the common odds ratio for any shift towards a better outcome in the intervention group, analyzed by multivariable ordinal logistic regression. Secondary trial endpoints: Secondary outcome measures include data on quality of life, cognitive functioning, and the use of resources. Cost-effectiveness will be assessed, separately for Belgium and for the Netherlands, adhering to 'KCE' and 'Zorginstituut' guidelines for pharmaco-economic evaluations, respectively. Trial design: This will be a comparative effectiveness study, comparing two standard treatment regimens. We will conduct a prospective multicentre trial with randomized treatment allocation, open label treatment, and blinded endpoint assessment on twenty intensive care units in the Netherlands and Belgium. Trial population: The study population consists of adult comatose patients after out of hospital cardiac arrest and successful cardiopulmonary resuscitation, admitted on the intensive care unit of any of the participating centres, with ESE on continuous EEG. Continuous EEG is part of standard care in all participating hospitals. For the definition of ESE, we adhere to international consensus criteria. Interventions: Treatment in the intervention group will consist of standard care completed with anti-seizure treatment according to protocols for clinically overt status epilepticus with the goal of definitive seizure suppression. This consists of a stepwise approach, step 1 being a single dose of a parenteral benzodiazepine (lorazepam, midazolam, or diazepam) and a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide), step 2, a second parenteral anti-seizure medication plus a first continuous parenteral sedative agent (midazolam or propofol), and step 3, a second continuous parenteral sedative agent (midazolam, propofol, or ketamine). Each next step will be taken as soon as possible (within 30 minutes) if the previous step was insufficiently effective to suppress ESE. The control group will receive standard care without anti-seizure treatment.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 150 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | Treatment of ELectrographic STatus Epilepticus After Cardiopulmonary Resuscitation-2: Multicenter Randomised Clinical Trial and Health Economic Evaluation of Anti-seizure Treatment in Comatose Cardiac Arrest Patients With SE on Continuous EEG |
| Actual Study Start Date : | 2025-01 |
| Estimated Primary Completion Date : | 2029-12 |
| Estimated Study Completion Date : | 2030-12 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Saint-Pierre University Hospital Center
Brussels, Belgium,
Not yet recruiting
Brussels University Hospital
Brussels, Belgium,
Not yet recruiting
University Hospital Brussels
Brussels, Belgium,
Not yet recruiting
Marie Curie University Hospital Center
Charleroi, Belgium,
Not yet recruiting
Hospital East Limburg
Genk, Belgium,
Not yet recruiting
Ghent University Hospital
Gent, Belgium,
Not yet recruiting
Christian Hospital Center - MontLégia
Liège, Belgium,
Not yet recruiting
Sart-Tilman University Hospital Center
Liège, Belgium,
Not yet recruiting
Amsterdam University Medical Center
Amsterdam, Netherlands,
Not yet recruiting
Rhinestate Hospital
Arnhem, Netherlands,
Not yet recruiting
Catharina Hospital
Eindhoven, Netherlands,
Not yet recruiting
Medical Spectrum Twente
Enschede, Netherlands,
Not yet recruiting
University Medical Center Groningen
Groningen, Netherlands,
Not yet recruiting
Leiden University Medical Center
Leiden, Netherlands,
Not yet recruiting
St. Antonius Hospital
Nieuwegein, Netherlands,
Not yet recruiting
Canisius Wilhelmina Hospital
Nijmegen, Netherlands,
Not yet recruiting
Radboud University Medical Center
Nijmegen, Netherlands,
Not yet recruiting
Erasmus University Medical Center
Rotterdam, Netherlands,
Not yet recruiting
Maasstad Hospital
Rotterdam, Netherlands,
Not yet recruiting
VieCuri Medical Center
Venlo, Netherlands,